Kairos Pharma, Ltd. (NYSEAMERICAN:KAPA) Short Interest Down 28.3% in September

Kairos Pharma, Ltd. (NYSEAMERICAN:KAPA) saw a significant decline in short interest in September. As of September 15th, there was short interest totaling 361,700 shares, a decline of 28.3% from the August 31st total of 504,700 shares. Based on an average daily volume of 5,060,000 shares, the days-to-cover ratio is currently 0.1 days. Currently, 4.1% of the company’s stock are sold short. Currently, 4.1% of the company’s stock are sold short. Based on an average daily volume of 5,060,000 shares, the days-to-cover ratio is currently 0.1 days.

Wall Street Analyst Weigh In

Separately, D. Boral Capital reiterated a “buy” rating and set a $9.00 price objective on shares of Kairos Pharma in a research note on Tuesday. Three investment analysts have rated the stock with a Buy rating, According to MarketBeat, Kairos Pharma presently has a consensus rating of “Buy” and an average price target of $8.33.

Kairos Pharma Stock Up 7.4%

NYSEAMERICAN KAPA opened at $1.31 on Thursday. The firm has a market cap of $27.17 million and a price-to-earnings ratio of -3.85. The business has a 50-day moving average price of $1.27 and a 200-day moving average price of $0.95. Kairos Pharma has a twelve month low of $0.40 and a twelve month high of $3.25.

Institutional Investors Weigh In On Kairos Pharma

An institutional investor recently bought a new position in Kairos Pharma stock. Armistice Capital LLC acquired a new stake in shares of Kairos Pharma, Ltd. (NYSEAMERICAN:KAPA) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 1,404,000 shares of the company’s stock, valued at approximately $1,314,000. Armistice Capital LLC owned 10.25% of Kairos Pharma at the end of the most recent reporting period.

Kairos Pharma Company Profile

We are a clinical-stage biopharmaceutical company advancing therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer and glioblastoma.